| Autor: |
F. Furmanik, B. Karczmarek-Borowska, K. Paprota |
| Rok vydání: |
1996 |
| Předmět: |
|
| Zdroj: |
European Journal of Cancer. 32:S10 |
| ISSN: |
0959-8049 |
| DOI: |
10.1016/0959-8049(96)84804-0 |
| Popis: |
The efficacy of surgery for patients with locally advanced non-small cell lung cancer is limited. From February 1993 to September 1994 32 patients with non-small cell lung cancer (NSCLC) entered a multimodality treatment study with neoadjuvant chemotherapy (Cisplatin+Vepesid) and surgery at Department of Cardiothoracic Surgery in a Medical Academy in Lublin, Poland. Twenty five patients (22 stage IIIa and 3 stage IIIb) have completed the chemotherapy and are available for evaluation of response, toxicity. surgical eligibility and resection rate. The objective response rate to chemotherapy was 56%. The chemotherapy was well-tolerated. Twenty two patients (88%) had a complete resection. No treatment-related mortality was observed. The postoperative complications were observed in 5 of 22 (23%) complete resected cases. After a median follow-up of 16 months (3–32) IS patients are still alive (60%). The authors conclude that Cisplatin and Vepesid is an effective neoadjuvant regimen for NSCLC in stage III. Applied regimen was not connected with increasing rate of postoperative complications. A longer follow-up is needed to assess the impact of this multimodality approach on long-term survival. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect